<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00609336</url>
  </required_header>
  <id_info>
    <org_study_id>6511</org_study_id>
    <secondary_id>NCI-2010-00553</secondary_id>
    <secondary_id>6511</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT00609336</nct_id>
  </id_info>
  <brief_title>Perioperative Therapy for Resectable Pancreatic Cancer</brief_title>
  <official_title>A Phase II Study Induction Chemotherapy, Neoadjuvant Chemoradiotherapy, Surgical Resection and Adjuvant Chemotherapy for Patients With Locally Advanced, Resectable Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well giving combination chemotherapy together with
      intensity-modulated radiation therapy (IMRT) and surgery works in treating patients with
      localized pancreatic cancer that can be removed by surgery. Drugs used in chemotherapy, such
      as gemcitabine hydrochloride, docetaxel, capecitabine, and oxaliplatin, work in different
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
      dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized
      radiation therapy, such as IMRT, that delivers a high dose of radiation directly to the tumor
      may kill more tumor cells and cause less damage to normal tissue. Giving more than one drug
      (combination chemotherapy) together with intensity-modulated radiation therapy before surgery
      may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
      Giving chemotherapy after surgery may kill any tumor cells that remain after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To estimate the median overall survival of patients with adenocarcinoma of the pancreas
      treated with induction chemotherapy, neoadjuvant chemoradiotherapy, surgical resection and
      adjuvant chemotherapy.

      SECONDARY OBJECTIVES:

      I. To determine the percent of patients surviving at annual intervals through five years.

      II. To determine the median recurrence free survival following pancreaticoduodenectomy.

      III. To determine the clinical response rate to neoadjuvant chemotherapy and
      chemoradiotherapy.

      IV. To determine the pathologic response rate to neoadjuvant chemotherapy and
      chemoradiotherapy.

      V. To determine the cancer antigen (CA) 19-9 tumor marker response rate to neoadjuvant
      chemotherapy and chemoradiotherapy.

      VI. To determine the surgical completion rate and complication rate following neoadjuvant
      chemotherapy and chemoradiotherapy.

      VII. To determine the frequency and severity of toxicities associated with this treatment
      regimen.

      OUTLINE:

      INDUCTION CHEMOTHERAPY: Patients receive gemcitabine hydrochloride intravenously (IV) over 75
      minutes and docetaxel IV over 30 or 60 minutes on days 4 and 11. Patients also receive
      capecitabine orally (PO) twice daily (BID) on days 1-14. Treatment repeats every 21 days for
      3 courses in the absence of disease progression or unacceptable toxicity.

      NEOADJUVANT CHEMORADIOTHERAPY: Beginning no more than 14 days after completion of induction
      chemotherapy, patients receive capecitabine PO BID on days 1-14 and oxaliplatin IV over 2
      hours on days 1 and 8. Patients also undergo IMRT once daily on days 1-5 and 8-13.

      SURGICAL RESECTION: Approximately 2-6 weeks after completion of neoadjuvant
      chemoradiotherapy, patients undergo pancreaticoduodenectomy.

      ADJUVANT CHEMOTHERAPY: Beginning 4-10 weeks after surgery, patients receive gemcitabine
      hydrochloride IV over 30 minutes and oxaliplatin IV over 2 hours on day 1. Treatment repeats
      every 14 days for 4 courses in the absence of disease progression or unacceptable toxicity.
      Patients then receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15.
      Treatment repeats every 28 days for 2 courses in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Overall Survival of Patients With Adenocarcinoma of the Pancreas</measure>
    <time_frame>5 years</time_frame>
    <description>Time at which Kaplan-Meier estimate of overall survival drops below 50%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Surviving at 5 Years</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Kaplan-Meier estimate of overall survival at 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Recurrence Free Survival Following Pancreaticoduodenectomy</measure>
    <time_frame>From the date of pancreaticoduodenectomy to date of first observation of radiographic recurrence or death due to any cause, assessed up to 7 years</time_frame>
    <description>The appearance of radiographic findings consistent with recurrent tumor at the local resection site or at a distant location is considered a radiographic recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response Rate to Neoadjuvant Chemotherapy and Chemoradiotherapy</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>Assessed using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic Response Rate (Complete, Near-complete, Partial) to Neoadjuvant Chemotherapy and Chemoradiotherapy</measure>
    <time_frame>Up to 7 years</time_frame>
    <description>The resected pancreaticoduodenectomy specimen and accompanying lymph nodes will be staged according to American Joint Committee on Cancer 6th Edition incorporating the prefix y to indicate a specimen status-post neoadjuvant treatment (ypTNM). Cancer 2012;118:1382-90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CA 19-9 Tumor Marker Response Rate to Neoadjuvant Chemotherapy and Chemoradiotherapy</measure>
    <time_frame>Up to 26 weeks after surgery</time_frame>
    <description>Biochemical response is a decrease of &gt;= 50% of CA 19-9 serum tumor marker in patients with elevated CA 19-9 at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Completion Rate and Complication Rate</measure>
    <time_frame>Up to 6 weeks following the completion of chemoradiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Severity of Toxicities Associated With This Treatment Regimen as Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0</measure>
    <time_frame>Up to 26 weeks after surgery (the end of adjuvant chemotherapy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients Surviving at Annual Intervals</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Adenocarcinoma of the Pancreas</condition>
  <condition>Stage IA Pancreatic Cancer</condition>
  <condition>Stage IB Pancreatic Cancer</condition>
  <condition>Stage IIA Pancreatic Cancer</condition>
  <condition>Stage IIB Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy, radiation, pancreaticoduodenectomy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, radiation, pancreaticoduodenectomy)</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>difluorodeoxycytidine hydrochloride</other_name>
    <other_name>gemcitabine</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, radiation, pancreaticoduodenectomy)</arm_group_label>
    <other_name>RP 56976</other_name>
    <other_name>Taxotere</other_name>
    <other_name>TXT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (chemotherapy, radiation, pancreaticoduodenectomy)</arm_group_label>
    <other_name>CAPE</other_name>
    <other_name>Ro 09-1978/000</other_name>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
    <description>Undergo IMRT</description>
    <arm_group_label>Treatment (chemotherapy, radiation, pancreaticoduodenectomy)</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, radiation, pancreaticoduodenectomy)</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>L-OHP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>pancreatic surgical procedure</intervention_name>
    <description>Undergo pancreaticoduodenectomy</description>
    <arm_group_label>Treatment (chemotherapy, radiation, pancreaticoduodenectomy)</arm_group_label>
    <other_name>pancreatic surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo therapeutic conventional surgery</description>
    <arm_group_label>Treatment (chemotherapy, radiation, pancreaticoduodenectomy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (chemotherapy, radiation, pancreaticoduodenectomy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed diagnosis of localized,
             resectable or borderline resectable, pancreatic adenocarcinoma T1-T3, N0-N1, M0; stage
             is determined by helical multi-phase computed tomography (CT) and/or endoscopic
             ultrasound according to published guidelines; resectability is determined by the
             treating surgeon and published guidelines (National Comprehensive Cancer Network)

          -  Resectable Disease- Head/Body/Tail of pancreas:

               -  No distant metastases

               -  Clear fat plane around celiac and superior mesenteric arteries (SMA)

               -  Patent superior mesenteric vein (SMV) and portal vein (PV)

          -  Borderline Resectable Disease -Head/Body of pancreas:

               -  Tumor abutment on SMA

               -  SMV/portal vein impingement or occlusion if involving only a short segment, with
                  open vein both proximally and distally (if proximal vein is occluded up to the
                  portal vein branches then disease is unresectable)

               -  Colon or mesocolon invasion

               -  Gastroduodenal artery (GDA) encasement up to origin at hepatic artery

          -  Tail of pancreas:

               -  Adrenal, colon or mesocolon, or kidney invasion

               -  Preoperative evidence of biopsy-positive peripancreatic lymph node

          -  No prior therapy for pancreatic cancer

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2 (Karnofsky &gt;= 60%)

          -  Leucocytes &gt;= 3,000/uL

          -  Absolute Neutrophil Count &gt;= 1,500/uL

          -  Platelets &gt;= 100,000/uL

          -  Total Bilirubin:

               -  If within normal limits (WNL) to =&lt; 2.0, the subject is eligible

               -  If &gt; 2.0 - &lt; 6.0, subject is eligible IF they have a biliary stent and total
                  bilirubin is decreasing

               -  If &gt;= 6.0, subject is not eligible

          -  Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvic transaminase [SGPT]) =&lt;
             2.5 X institutional upper limit of normal or =&lt; 1.5 X upper limit of normal (ULN) if
             alkaline phosphatase (Alk Phos) &gt; 2.5 X ULN or if the subject has a biliary stent and
             the liver function tests (LFTs) are decreasing the subject is eligible

          -  Creatinine clearance &gt;= 30%

          -  Negative pregnancy test for women of childbearing potential; women of childbearing
             potential and men must agree to use adequate contraception (hormonal or barrier method
             of birth control; abstinence) prior to study entry and for the duration of study
             participation; should a woman become pregnant or suspect she is pregnant while
             participating in this study, she should inform her treating physician immediately

          -  Ability to swallow and retain oral medication

          -  Ability to understand and willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients may not be receiving any other investigational agents

          -  Histology other than adenocarcinoma

          -  Patients with permanently unresectable pancreatic adenocarcinoma as determined by the
             treating physician and published guidelines (National Comprehensive Cancer Network)

          -  Unresectable disease

          -  Head of pancreas:

               -  Distant metastases (includes celiac and/or para-aortic)

               -  SMA, celiac encasement

               -  SMV/portal occlusion

               -  Aortic, inferior vena cava (IVC) invasion or encasement

               -  Invasion of SMV below transverse mesocolon

          -  Body of pancreas:

               -  Distant metastases (includes celiac and/or para-aortic); at the discretion of the
                  treating surgeon, body and tail lesions that have positive celiac and/or
                  para-aortic nodes in close vicinity to the primary may be borderline rather than
                  unresectable

               -  SMA, celiac, hepatic encasement

               -  SMV/portal extended occlusion

               -  Aortic invasion

          -  Tail of pancreas:

               -  Distant metastases (includes celiac and/or para-aortic)

               -  SMA, celiac encasement

               -  Rib, vertebral invasion

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to gemcitabine, docetaxel, capecitabine, oxaliplatin or other agents used
             in the study

          -  Patients who have received prior chemotherapy or radiotherapy for the diagnosis of
             pancreatic cancer

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Inability to comply with study and/or follow-up procedures

          -  Pregnancy or lactation

          -  Human immunodeficiency virus (HIV)-positive patients receiving combination
             anti-retroviral therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Coveler</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2008</study_first_submitted>
  <study_first_submitted_qc>February 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2008</study_first_posted>
  <results_first_submitted>March 21, 2017</results_first_submitted>
  <results_first_submitted_qc>June 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2017</results_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Andrew Coveler</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
          <description>See Detailed Description
gemcitabine hydrochloride: Given IV
docetaxel: Given IV
capecitabine: Given PO
intensity-modulated radiation therapy: Undergo IMRT
oxaliplatin: Given IV
pancreatic surgical procedure: Undergo pancreaticoduodenectomy
therapeutic conventional surgery: Undergo therapeutic conventional surgery
gemcitabine: Given IV
oxaliplatin: Given IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Surgery</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>LA or Met at Surgery</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All eligible patients</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
          <description>See Detailed Description
gemcitabine hydrochloride: Given IV
docetaxel: Given IV
capecitabine: Given PO
intensity-modulated radiation therapy: Undergo IMRT
oxaliplatin: Given IV
pancreatic surgical procedure: Undergo pancreaticoduodenectomy
therapeutic conventional surgery: Undergo therapeutic conventional surgery
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="46" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Overall Survival of Patients With Adenocarcinoma of the Pancreas</title>
        <description>Time at which Kaplan-Meier estimate of overall survival drops below 50%</description>
        <time_frame>5 years</time_frame>
        <population>All eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
            <description>See Detailed Description
gemcitabine hydrochloride: Given IV
docetaxel: Given IV
capecitabine: Given PO
intensity-modulated radiation therapy: Undergo IMRT
oxaliplatin: Given IV
pancreatic surgical procedure: Undergo pancreaticoduodenectomy
therapeutic conventional surgery: Undergo therapeutic conventional surgery
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Median Overall Survival of Patients With Adenocarcinoma of the Pancreas</title>
          <description>Time at which Kaplan-Meier estimate of overall survival drops below 50%</description>
          <population>All eligible patients</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6" lower_limit="14.2" upper_limit="58.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients Surviving at 5 Years</title>
        <description>Kaplan-Meier estimate of overall survival at 5 years</description>
        <time_frame>Up to 5 years</time_frame>
        <population>all eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
            <description>See Detailed Description
gemcitabine hydrochloride: Given IV
docetaxel: Given IV
capecitabine: Given PO
intensity-modulated radiation therapy: Undergo IMRT
oxaliplatin: Given IV
pancreatic surgical procedure: Undergo pancreaticoduodenectomy
therapeutic conventional surgery: Undergo therapeutic conventional surgery
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients Surviving at 5 Years</title>
          <description>Kaplan-Meier estimate of overall survival at 5 years</description>
          <population>all eligible patients</population>
          <units>percentage of eligible pts alive</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Recurrence Free Survival Following Pancreaticoduodenectomy</title>
        <description>The appearance of radiographic findings consistent with recurrent tumor at the local resection site or at a distant location is considered a radiographic recurrence.</description>
        <time_frame>From the date of pancreaticoduodenectomy to date of first observation of radiographic recurrence or death due to any cause, assessed up to 7 years</time_frame>
        <population>Among eligible patients who received surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
            <description>See Detailed Description
gemcitabine hydrochloride: Given IV
docetaxel: Given IV
capecitabine: Given PO
intensity-modulated radiation therapy: Undergo IMRT
oxaliplatin: Given IV
pancreatic surgical procedure: Undergo pancreaticoduodenectomy
therapeutic conventional surgery: Undergo therapeutic conventional surgery
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Median Recurrence Free Survival Following Pancreaticoduodenectomy</title>
          <description>The appearance of radiographic findings consistent with recurrent tumor at the local resection site or at a distant location is considered a radiographic recurrence.</description>
          <population>Among eligible patients who received surgery</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" lower_limit="12.5">Upper limit is infinite.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Response Rate to Neoadjuvant Chemotherapy and Chemoradiotherapy</title>
        <description>Assessed using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee.</description>
        <time_frame>Up to 7 years</time_frame>
        <population>Clinical response not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
            <description>See Detailed Description
gemcitabine hydrochloride: Given IV
docetaxel: Given IV
capecitabine: Given PO
intensity-modulated radiation therapy: Undergo IMRT
oxaliplatin: Given IV
pancreatic surgical procedure: Undergo pancreaticoduodenectomy
therapeutic conventional surgery: Undergo therapeutic conventional surgery
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response Rate to Neoadjuvant Chemotherapy and Chemoradiotherapy</title>
          <description>Assessed using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee.</description>
          <population>Clinical response not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pathologic Response Rate (Complete, Near-complete, Partial) to Neoadjuvant Chemotherapy and Chemoradiotherapy</title>
        <description>The resected pancreaticoduodenectomy specimen and accompanying lymph nodes will be staged according to American Joint Committee on Cancer 6th Edition incorporating the prefix y to indicate a specimen status-post neoadjuvant treatment (ypTNM). Cancer 2012;118:1382-90</description>
        <time_frame>Up to 7 years</time_frame>
        <population>all eligible patients with non-missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
            <description>See Detailed Description
gemcitabine hydrochloride: Given IV
docetaxel: Given IV
capecitabine: Given PO
intensity-modulated radiation therapy: Undergo IMRT
oxaliplatin: Given IV
pancreatic surgical procedure: Undergo pancreaticoduodenectomy
therapeutic conventional surgery: Undergo therapeutic conventional surgery
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Response Rate (Complete, Near-complete, Partial) to Neoadjuvant Chemotherapy and Chemoradiotherapy</title>
          <description>The resected pancreaticoduodenectomy specimen and accompanying lymph nodes will be staged according to American Joint Committee on Cancer 6th Edition incorporating the prefix y to indicate a specimen status-post neoadjuvant treatment (ypTNM). Cancer 2012;118:1382-90</description>
          <population>all eligible patients with non-missing data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CA 19-9 Tumor Marker Response Rate to Neoadjuvant Chemotherapy and Chemoradiotherapy</title>
        <description>Biochemical response is a decrease of &gt;= 50% of CA 19-9 serum tumor marker in patients with elevated CA 19-9 at baseline.</description>
        <time_frame>Up to 26 weeks after surgery</time_frame>
        <population>Biomarker data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
            <description>See Detailed Description
gemcitabine hydrochloride: Given IV
docetaxel: Given IV
capecitabine: Given PO
intensity-modulated radiation therapy: Undergo IMRT
oxaliplatin: Given IV
pancreatic surgical procedure: Undergo pancreaticoduodenectomy
therapeutic conventional surgery: Undergo therapeutic conventional surgery
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>CA 19-9 Tumor Marker Response Rate to Neoadjuvant Chemotherapy and Chemoradiotherapy</title>
          <description>Biochemical response is a decrease of &gt;= 50% of CA 19-9 serum tumor marker in patients with elevated CA 19-9 at baseline.</description>
          <population>Biomarker data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surgical Completion Rate and Complication Rate</title>
        <time_frame>Up to 6 weeks following the completion of chemoradiotherapy</time_frame>
        <population>all eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
            <description>See Detailed Description
gemcitabine hydrochloride: Given IV
docetaxel: Given IV
capecitabine: Given PO
intensity-modulated radiation therapy: Undergo IMRT
oxaliplatin: Given IV
pancreatic surgical procedure: Undergo pancreaticoduodenectomy
therapeutic conventional surgery: Undergo therapeutic conventional surgery
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Surgical Completion Rate and Complication Rate</title>
          <population>all eligible patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Completion rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complication rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Severity of Toxicities Associated With This Treatment Regimen as Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0</title>
        <time_frame>Up to 26 weeks after surgery (the end of adjuvant chemotherapy)</time_frame>
        <population>All eligible patients</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
            <description>See Detailed Description
gemcitabine hydrochloride: Given IV
docetaxel: Given IV
capecitabine: Given PO
intensity-modulated radiation therapy: Undergo IMRT
oxaliplatin: Given IV
pancreatic surgical procedure: Undergo pancreaticoduodenectomy
therapeutic conventional surgery: Undergo therapeutic conventional surgery
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Severity of Toxicities Associated With This Treatment Regimen as Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0</title>
          <population>All eligible patients</population>
          <units>occurrence of toxicities</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Grade 2 CTCAE toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Grade 3 CTCAE toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Grade 4 CTCAE toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients Surviving at Annual Intervals</title>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
            <description>See Detailed Description
gemcitabine hydrochloride: Given IV
docetaxel: Given IV
capecitabine: Given PO
intensity-modulated radiation therapy: Undergo IMRT
oxaliplatin: Given IV
pancreatic surgical procedure: Undergo pancreaticoduodenectomy
therapeutic conventional surgery: Undergo therapeutic conventional surgery
gemcitabine: Given IV
oxaliplatin: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients Surviving at Annual Intervals</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Year 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Year 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment (Chemotherapy, Radiation, Pancreaticoduodenectomy)</title>
          <description>See Detailed Description
gemcitabine hydrochloride: Given IV
docetaxel: Given IV
capecitabine: Given PO
intensity-modulated radiation therapy: Undergo IMRT
oxaliplatin: Given IV
pancreatic surgical procedure: Undergo pancreaticoduodenectomy
therapeutic conventional surgery: Undergo therapeutic conventional surgery
gemcitabine: Given IV
oxaliplatin: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Fever, Neutropenic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="31" subjects_affected="24" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Thrombotic Microangiopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Transient Ischemic Attacks</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Entero Cutaneous Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Lower GI Bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Shoulder Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Cholangitis With Stent Occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Cholecystic Abcess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Intrahepatic Absesses</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Non-Malignant Ascitess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Obstructive Jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Portal Vein Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Transaminitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Bacterial Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated Bilirubin</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypoatremic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nose Bleeds</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-foot Syndrome</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Anasarca</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Transaminase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated Bilirubin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Maculopapular Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand Foot Syndrome</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Maculopapular Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Rash - Upper Torso</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Coveler, MD</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-288-7509</phone>
      <email>acoveler@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

